Logiciel Solutions clarifies delay in disclosing senior management appointments
Logiciel Solutions clarified to BSE that the delay in disclosing senior management appointments was due to an inadvertent oversight regarding regulatory classification. The Board had previously approved a USD 10,000 investment in a US subsidiary and noted key appointments in sales and healthcare, alongside the launch of an AI R&D practice.

*this image is generated using AI for illustrative purposes only.
Logiciel Solutions Limited has clarified to BSE Limited that the delay in disclosing the appointment of Senior Management Personnel was due to an inadvertent interpretational oversight regarding the classification of these roles under Regulation 16 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company, in its letter dated July 16, 2026, stated there was no intention to withhold material information or circumvent regulatory requirements. The clarification follows a discrepancy remark received by the exchange regarding the Corporate Announcement submitted on July 14, 2026.
Board Meeting Outcomes
The Board of Directors, at its meeting held on July 14, 2026, had approved several key strategic initiatives. These included the approval of an investment of USD 10,000 in Logiciel Solutions Inc., USA, to establish a wholly-owned subsidiary. The subsidiary, incorporated in Delaware on June 15, 2026, aims to strengthen the company's presence in the North American market and support its IT Services and IT Staffing business.
Senior Management Appointments
The meeting also took note of the appointments of Mr. Anshul Sharma as Vice President — Sales and Mr. Ram Prakash Varanasi as Practice Head — Healthcare. Mr. Sharma, effective April 21, 2026, brings over 12 years of experience in business development across the North American market. Mr. Varanasi, effective June 24, 2026, has 15 years of domain experience in healthcare technology. The disclosure regarding these appointments was delayed, prompting the company to submit the clarification to the exchange.
Strategic Initiatives
Additionally, the Board noted the establishment of an AI Research & Development Practice effective from March 2026. This initiative is led by Mr. Kumar Gaurav and comprises a four-member dedicated AI engineering team. The practice aims to develop proprietary AI tools and explore AI product opportunities, with funding sourced from the Research & Development objects of the company's IPO. The company has stated that appropriate internal compliance measures have been strengthened to ensure timely reporting of all such events in the future.
| Particulars | Details |
|---|---|
| Target Entity | Logiciel Solutions Inc., USA |
| Investment Amount | USD 10,000 |
| Shares Subscribed | 10,00,000 shares |
| Par Value | USD 0.01 per share |
| Percentage Acquired | 100% (Wholly-owned subsidiary) |
| Date of Incorporation | June 15, 2026 |
Historical Stock Returns for Logiciel Solutions
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| 0.0% | -2.64% | -6.73% | -38.13% | -77.33% | -77.33% |
What specific revenue targets has Logiciel Solutions set for its new North American subsidiary over the next fiscal year?
How will the new AI R&D Practice differentiate the company's proprietary tools from existing competitors in the healthcare technology sector?
What are the projected timelines for the first commercial release of AI products developed by the new engineering team?






























